BRIEF-Sellas Announces Positive Overall Survival In Cohort 3 From Phase 2 Trial Of Sls009 In R/R Aml

Reuters04-08

April 8 (Reuters) - Sellas Life Sciences Group Inc SLS.O:

SELLAS ANNOUNCES POSITIVE OVERALL SURVIVAL IN COHORT 3 FROM THE ONGOING PHASE 2 TRIAL OF SLS009 IN R/R AML
SELLAS LIFE SCIENCES GROUP INC: TRIAL CONTINUES WITH FULL DATA AND FDA REGULATORY PATH FEEDBACK EXPECTED IN 1H 2025
SELLAS LIFE SCIENCES GROUP INC: OVERALL RESPONSE RATE $(ORR.AU)$ OF 67% ACHIEVED IN PATIENTS WITH AML-MRC

Source text: ID:nGNX7dS0Gz

Further company coverage: SLS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2525890936?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-04-08 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525890936","market":"nz","top_or_hot":-1,"title":"BRIEF-Sellas Announces Positive Overall Survival In Cohort 3 From Phase 2 Trial Of Sls009 In R/R Aml","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sellas Announces Positive Overall Survival In Cohort 3 From Phase 2 Trial Of Sls009 In R/R Aml</title></head><body><p><span>April 8 (Reuters)</span><span> - </span>Sellas Life Sciences Group Inc <span>SLS.O</span>:</p><ul><li><p>SELLAS ANNOUNCES POSITIVE OVERALL SURVIVAL IN <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> 3 FROM THE ONGOING PHASE 2 TRIAL OF SLS009 IN R/R AML</p></li><li><p>SELLAS LIFE SCIENCES GROUP INC: TRIAL CONTINUES WITH FULL DATA AND FDA REGULATORY PATH <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> EXPECTED IN 1H 2025</p></li><li><p>SELLAS LIFE SCIENCES GROUP INC:  OVERALL RESPONSE RATE <a href=\"https://laohu8.com/S/ORR.AU\">$(ORR.AU)$</a> OF 67% ACHIEVED IN PATIENTS WITH AML-MRC</p></li></ul><p>Source text: <span>ID:nGNX7dS0Gz</span></p><p>Further company coverage: <span>SLS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sellas Announces Positive Overall Survival In Cohort 3 From Phase 2 Trial Of Sls009 In R/R Aml</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sellas Announces Positive Overall Survival In Cohort 3 From Phase 2 Trial Of Sls009 In R/R Aml\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-08 21:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sellas Announces Positive Overall Survival In Cohort 3 From Phase 2 Trial Of Sls009 In R/R Aml</title></head><body><p><span>April 8 (Reuters)</span><span> - </span>Sellas Life Sciences Group Inc <span>SLS.O</span>:</p><ul><li><p>SELLAS ANNOUNCES POSITIVE OVERALL SURVIVAL IN <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> 3 FROM THE ONGOING PHASE 2 TRIAL OF SLS009 IN R/R AML</p></li><li><p>SELLAS LIFE SCIENCES GROUP INC: TRIAL CONTINUES WITH FULL DATA AND FDA REGULATORY PATH <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> EXPECTED IN 1H 2025</p></li><li><p>SELLAS LIFE SCIENCES GROUP INC:  OVERALL RESPONSE RATE <a href=\"https://laohu8.com/S/ORR.AU\">$(ORR.AU)$</a> OF 67% ACHIEVED IN PATIENTS WITH AML-MRC</p></li></ul><p>Source text: <span>ID:nGNX7dS0Gz</span></p><p>Further company coverage: <span>SLS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1XV:1","article_id":"2525890936","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525890936","pubTimestamp":1744118868,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Sellas Announces Positive Overall Survival In Cohort 3 From Phase 2 Trial Of Sls009 In R/R AmlApril 8 (Reuters) - Sellas Life Sciences Group Inc SLS.O:SELLAS ANNOUNCES POSITIVE OVERALL SURVIVAL ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简介-Sellas宣布Sls009治疗R/R Aml的2期试验队列3的总生存期为阳性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLS":0.9},"content_text":"BRIEF-Sellas Announces Positive Overall Survival In Cohort 3 From Phase 2 Trial Of Sls009 In R/R AmlApril 8 (Reuters) - Sellas Life Sciences Group Inc SLS.O:SELLAS ANNOUNCES POSITIVE OVERALL SURVIVAL IN COHORT 3 FROM THE ONGOING PHASE 2 TRIAL OF SLS009 IN R/R AMLSELLAS LIFE SCIENCES GROUP INC: TRIAL CONTINUES WITH FULL DATA AND FDA REGULATORY PATH FEEDBACK EXPECTED IN 1H 2025SELLAS LIFE SCIENCES GROUP INC:  OVERALL RESPONSE RATE $(ORR.AU)$ OF 67% ACHIEVED IN PATIENTS WITH AML-MRCSource text: ID:nGNX7dS0GzFurther company coverage: SLS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2525890936"}